IgA肾病患者肠黏膜屏障功能与血清Gd-IgA1相关性研究*

doi:10.3969/j.issn.1671-2587.2022.03.017

临床输血与检验 ›› 2022, Vol. 24 ›› Issue (3): 357-362.DOI: 10.3969/j.issn.1671-2587.2022.03.017

IgA肾病患者肠黏膜屏障功能与血清Gd-IgA1相关性研究^*

肖勇, 贺海东, 胡屏, 孙蔚倩, 徐旭东, 唐余燕

201900 上海交通大学医学院附属第九人民医院急诊科（肖勇）,复旦大学附属闵行医院（上海市闵行区中心医院肾脏科）（贺海东,胡屏,孙蔚倩,徐旭东,唐余燕）

收稿日期:2021-09-09 出版日期:2022-06-20 发布日期:2022-06-22
通讯作者: 唐余燕,女,主治医师,硕士,主要从事IgA肾病的免疫发病机制及治疗,（E-mail）tangyuyan361113248@163.com。
作者简介:肖勇（1984-）,男,安徽安庆人,主治医师,本科,主要从事急诊创伤性研究,（E-mail）xiaoyong373@163.com。
基金资助:
*本课题受国家自然科学基金（No. 81774060）; 上海市卫计委科基基金（No. 20184Y0040）; 闵行高层次专科骨干医师培训计划（No. 2020MZYS19）资助

The Correlation of Intestinal Mucosal Barrier Function with Serum Gd-IgA1 in Patients with IgA Nephropathy

XIAO Yong, HE Hai-dong, HU Ping, et al

Department of Emergency. Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 201900

Received:2021-09-09 Online:2022-06-20 Published:2022-06-22

摘要/Abstract

摘要： 目的探讨肠黏膜屏障功能与血清Gd-IgA1表达水平的相关性。方法收集2019年1月~2019年12月我科住院病人,以首次经肾活检证实为IgA肾病患者45例作为IgA肾病组,以正常健康人群25例作为对照组。检测所有血清样本中炎症因子水平（IL-6及TNF-α）、肠黏膜屏障损伤指标（D-LAC 、DAO、sICAM-1及 LPS）及Gd-IgA1 水平,同时收集患者的一般资料及临床指标（肾功能、24 h尿蛋白定量及IgA水平）,并对上述指标进行统计学分析。结果与对照组相比,实验组患者炎症因子水平、肠道黏膜屏障损伤指标及Gd-IgA1水平升高,差异具有统计学意义（P<0.05）,并且实验组患者血清Gd-IgA1水平与肠道屏障损伤指标呈正相关（P<0.05）。结论 IgA肾病患者血清Gd-IgA1水平升高,肠黏膜屏障功能可能参与了Gd-IgA1的表达,这为IgA肾病的治疗监测及判断预后开拓新方向。

关键词: IgA肾病, Gd-IgA1, 肠道屏障, 治疗

Abstract: Objective To explore the correlation between intestinal mucosal barrier damage index and serum Gd-IgA1 expression levels. Methods In our retrospective review from January 2019 to December 2019,45 patients with IgA nephropathy（IgAN）confirmed by renal biopsy for the first time were enrolled as the IgA nephropathy group and 25 healthy individuals in the Physical Examination Center of our hospital as the control group.The levels of inflammatory factors （TNF-α and IL-6）,intestinal mucosal barrier damage index（DAO,D-LAC,sICAM-1 and LPS）and Gd-IgA1 levels were examined in all serum samples,and the general data,renal function,24 h urine protein quantification,and IgA levels of the patients were collected for statistical analysis. Results Compared with the healthy controls,inflammatory factors, intestinal mucosal barrier damage index and Gd-IgA1 levels were significantly higher in patients with IgAN（P<0.05）,and serum Gd-IgA1 levels in IgAN were positively associated with them（P<0.05）. Conclusion The impaired intestinal mucosal barrier may be involved in the Gd-IgA1 expression, which could show promise in the diagnosis and treatment of IgAN.

Key words: IgA nephropathy, Galactose-deficient IgA1（Gd-IgA1）, Intestinal mucosa barrier, Treatment

中图分类号:

R692

肖勇, 贺海东, 胡屏, 孙蔚倩, 徐旭东, 唐余燕. IgA肾病患者肠黏膜屏障功能与血清Gd-IgA1相关性研究^*[J]. 临床输血与检验, 2022, 24(3): 357-362.

XIAO Yong, HE Hai-dong, HU Ping, et al. The Correlation of Intestinal Mucosal Barrier Function with Serum Gd-IgA1 in Patients with IgA Nephropathy[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(3): 357-362.

参考文献

[1] SCHENA F P,NISTOR I.Epidemiology of IgA nephropathy:a global perspective[J].Semin Nephrol,2018,38(5):435-442.
[2] HASTINGS M C,MOLDOVEANU Z,JULIAN B A,et al.Galactose-deficient IgA1 in African Americans with IgA nephropathy:serum levels and heritability[J]. Clin J Am Soc Nephrol,2010,5(11):2069-2074.
[3] CHEN P,YU G Z,ZHANG X,et al.Plasma galactose-deficient IgA1 and C3 and CKD progression in IgA nephropathy[J]. Clin J Am Soc Nephrol,2019,14(10):1458-1465.
[4] YEO S C,CHEUNG C K,BARRATT J.New insights into the pathogenesis of IgA nephropathy[J].Pediatr Nephrol,2018,33(5):763-777.
[5] ROLLINO C,VISCHINI G,COPPO R.IgA nephropathy and infections[J]. J Nephrol,2016,29(4):463-468.
[6] STECHER B,MAIER L S,HARDT W D.'Blooming' in the gut:how dysbiosis might contribute to pathogen evolution[J]. Nat Rev Microbiol,2013,11(4):277-284.
[7] COPPO R.The intestine-renal connection in IgA nephropathy[J].Nephrol Dial Transplant,2015,30(3):360-366.
[8] 肖勇,贺海东,胡屏,等. 血清Gd-IgA1水平与IgA肾病患者临床及病理特点的关系分析[J]. 临床输血与检验,2021,23(4):492-496.
[9] SUZUKI H,YASUTAKE J,MAKITA Y,et al.IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis[J]. Kidney Int,2018,93(3):700-705.
[10] WU I W,GAO S S,CHOU H C,et al.Integrative metagenomic and metabolomic analyses reveal severity-specific signatures of gut microbiota in chronic kidney disease[J]. Theranostics,2020,10(12):5398-5411.
[11] PROCTOR L M,CREASY H H,FETTWEIS J M,et al.The integrative human microbiome project[J]. Nature,2019,569(7758):641-648.
[12] WANG Y F,ZHENG L J,LIU Y,et al.The gut microbiota-inflammation-brain axis in end-stage renal disease:perspectives from default mode network[J]. Theranostics,2019,9(26):8171-8181.
[13] KAYAMA H,OKUMURA R,TAKEDA K.Interaction between the microbiota,epithelia,and immune cells in the intestine[J]. Annu Rev Immunol,2020,38:23-48.
[14] QIN W,ZHONG X,FAN J M,et al.External suppression causes the low expression of the Cosmc gene in IgA nephropathy[J].Nephrol Dial Transplant,2008,23(5):1608-1614.
[15] UEMATSU S,AKIRA S.Immune responses of TLR5(+) Lamina propria dendritic cells in enterobacterial infection[J]. J Gastroenterol,2009,44(8):803-811.
[16] HUANG Y H,ZHOU J,WANG S B,et al.Indoxyl sulfate induces intestinal barrier injury through IRF1-DRP1 axis-mediated mitophagy impairment[J]. Theranostics,2020,10(16):7384-7400.
[17] BROWN E M,KENNY D J,XAVIER R J.Gut microbiota regulation of T cells during inflammation and autoimmunity[J]. Annu Rev Immunol,2019,37:599-624.
[18] ROLLINO C,VISCHINI G,COPPO R.IgA nephropathy and infections[J]. J Nephrol,2016,29(4):463-468.
[19] TAJIK N,FRECH M,SCHULZ O,et al.Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis[J]. Nat Commun,2020,11(1):1995.
[20] GUO Y J,LI H L,LIU Z,et al.Impaired intestinal barrier function in a mouse model of hyperuricemia[J]. Mol Med Rep,2019,20(4):3292-3300.
[21] TUCKWELL K,GABAY C,SORNASSE T,et al.Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab[J]. Adv Rheumatol,2019,59(1):54.
[22] YANG X S,YAN L Y,HA D,et al.Changes in sICAM-1 and GM-CSF levels in skin tissue fluid and expression of IL-6,IL-17 and TNF-α in blood of patients with vitiligo[J]. Exp Ther Med,2019,17(1):408-412.
[23] FATHOLLAHI A,MASSOUD A,AMIRZARGAR A A,et al.sICAM-1,sVCAM-1 and sE-selectin levels in type 1 diabetes[J]. Fetal Pediatr Pathol,2018,37(1):69-73.

IgA肾病患者肠黏膜屏障功能与血清Gd-IgA1相关性研究^*

The Correlation of Intestinal Mucosal Barrier Function with Serum Gd-IgA1 in Patients with IgA Nephropathy

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	沈国栋, 栾建凤. 疑难血型肝衰竭患者紧急肝移植与输血策略——附1例报道[J]. 临床输血与检验, 2021, 23(6): 693-695.
[2]	陈学军, 王梦雅, 唐雀美, 沈月芳. 新生儿高胆红素血症换血治疗的现状及研究进展[J]. 临床输血与检验, 2021, 23(6): 696-699.
[3]	王文婷, 刘启旺, 张嵘, 党盼玉, 顾顺利, 胡兴斌, 刘杨, 尹文. 亲体子宫移植患者围术期临床用血情况的分析与探讨[J]. 临床输血与检验, 2021, 23(5): 551-555.
[4]	肖勇, 贺海东, 胡屏, 孙蔚倩, 徐旭东, 唐余燕. 血清Gd-IgA1水平与IgA肾病患者临床及病理特点的关系分析^*[J]. 临床输血与检验, 2021, 23(4): 492-496.
[5]	王颖颖, 郭笑寒, 臧亮, 邓雪莲. 1例核酸检测混检无反应性的HIV感染献血者的检出^*[J]. 临床输血与检验, 2021, 23(3): 389-391.
[6]	张源秦, 马怡然, 郝一文, 程大也. 胎母输血综合征辅助诊断与治疗进展^*[J]. 临床输血与检验, 2021, 23(3): 395-399.
[7]	迟红旭, 江颖, 姚欢, 田静, 李玲玲, 朱晓君, 刘晓敏, 张雷英, 孙桂香, 于洋. 非霍奇金淋巴瘤患者行外周血单个核细胞采集前后血细胞的变化及影响因素分析[J]. 临床输血与检验, 2021, 23(2): 156-162.
[8]	郑静娴, 李晓辉, 孙洪强. 儿童免疫性血小板减少症的临床观察及抗核抗体在其中作用的研究[J]. 临床输血与检验, 2021, 23(2): 231-235.
[9]	李翠莹. 胎儿新生儿溶血病的诊疗策略探讨^*[J]. 临床输血与检验, 2021, 23(1): 24-28.
[10]	王文婷, 党盼玉, 张保萍, 胡兴斌, 安群星, 尹文. 抗-D抗体致新生儿溶血病的输血策略及其预后疗效评估分析[J]. 临床输血与检验, 2021, 23(1): 38-40.
[11]	庄远, 汪德清. 传统血浆置换治疗如何适应现代医学的发展[J]. 临床输血与检验, 2020, 22(5): 472-476.
[12]	李剑平, 李晓丰, 赵立哲, 王宏阳, 李伟伟, 林园, 刘景汉. 输血相关治疗应用于新冠病毒肺炎救治中的思考^*[J]. 临床输血与检验, 2020, 22(3): 228-232.
[13]	沈季敏, 刘欣, 王兴兵. TLR-3激动剂联合TLR-9激动剂对树突状细胞细胞形态及免疫表型的影响*[J]. 临床输血与检验, 2020, 22(1): 71-76.
[14]	谭碧雯, 梁群, 陈健红, 李翊泉, 李莹. 输血相关铁过载评估及联合疗法与单一疗法比较研究[J]. 临床输血与检验, 2019, 21(5): 458-461.
[15]	朱群卉, 张青, 张研, 杨文平, 胡笛, 杜运, 廖晓琴, 李艳苹, 谭艳丽, 宋正芳, 曾艳. 输血护理规范化管理对血液病输血患者预后和生活质量的影响[J]. 临床输血与检验, 2019, 21(5): 548-551.